BASF's Twin Engine: Shareholder Payouts and Sunscreen Approval Drive Momentum
Published on 08/11/2026 at 03:13 | Redaktion boerse-global.de
The chemicals giant is firing on two fronts this month — returning capital to investors at a steady clip while unlocking a long-awaited regulatory win in the US personal care market. The combination has analysts circling, the share price climbing, and the company's restructuring narrative gaining credibility.
A New Chapter in US Sun Protection
BASF has secured US Food and Drug Administration approval for its UV filter Tinosorb S (bemotrizinol), a sunscreen ingredient long established in European formulations but previously unavailable to American cosmetics manufacturers. Alongside the green light, the company obtained an 18-month co-exclusive license from DSM Nutritional Products, giving it a clear runway to court US customers in the Care Chemicals division before competitors can follow.
The timing is fortunate. Just days earlier, on July 29, BASF reported second-quarter sales of €17.2 billion — a jump of €2.4 billion, or roughly 16 percent year over year. EBITDA before special items came in at €2.4 billion, ahead of analyst consensus, prompting management to raise its full-year guidance. The company also announced plans to repay bonds and loans worth €1.6 billion in nominal volume during the third quarter, a move aimed at trimming net debt.
Buybacks Keep Rolling
The capital return machine shows no signs of slowing. A fresh €1 billion share repurchase program kicked off on August 3 and is slated to run through April 2027. In its first week — between August 3 and 7 — BASF bought back 545,000 of its own shares on Xetra at a volume-weighted average price of €51.19 apiece.
That tranche follows an earlier €1.5 billion buyback completed between November 2025 and June 2026. Taken together, the company has committed to distributing €12 billion to shareholders across 2025 through 2028: €8 billion in dividends and €4 billion in buybacks. Management is also targeting a return on capital employed (ROCE) of roughly 10 percent by 2028.
While BASF's turnaround hinges on disciplined cost management and regulatory wins, your own workplace compliance shouldn't be left to chance. Many employers unknowingly miss critical safety documentation — leaving themselves exposed. A free toolkit with 41 ready-to-use checklists and templates helps you document risks properly and stay compliant. Download the free Risk Assessment Toolkit
For the current fiscal year, BASF has flagged a dividend of €2.36 per share, up from €2.25 for 2025. Second-quarter earnings per share came in at €4.78, a dramatic recovery from just €0.09 in the same period last year.
Cost Cutting With an Axe, Not Pruning Shears
The earnings rebound is inseparable from a sweeping cost-reduction drive. At the Ludwigshafen headquarters, BASF is eliminating 300 to 350 positions per month, with a target of 4,000 job cuts over two years. In IT, 1,800 roles have already shifted to India, and the company's Shared Service Center in Berlin — employing around 3,000 people — is slated to follow.
CEO Kamieth has been characteristically blunt about the approach, publicly advocating for sharper reductions in social welfare and labor market regulations and describing the strategy as taking "an axe rather than pruning shears" to costs. The remarks drew criticism but underscore management's conviction that efficiency gains must underwrite the generous shareholder payouts.
Structural Tweaks Across the Portfolio
Elsewhere, BASF India has decided to close its sulfation and low-temperature reactor units at the Dahej site in the Care Chemicals division. The affected operations contributed roughly 4 percent to the Indian subsidiary's revenue last year — a modest but visible portfolio adjustment.
In crop science, the company's agriculture division began the global registration process in late July for Replexor Active, a new PPO herbicide based on the active ingredient fendioxypyracil, designed to combat broadleaf weeds and grasses.
Analyst Sentiment Shifts
The combination of an earnings beat and ongoing buybacks has not gone unnoticed on the sell side. Kepler Capital Markets upgraded BASF from "Hold" to "Buy" on August 7, citing second-quarter results that comfortably exceeded market expectations. Deutsche Bank reaffirmed its rating on July 29 with a price target of €60 — the most bullish among recent calls. UBS and Berenberg have been more measured, setting targets of €55 and €50, respectively.
The market has responded in kind. The stock closed at €51.55 on Monday, up 0.41 percent on the day, and has gained roughly 16 percent since the start of the year. Over the past 30 days alone, the share price has advanced 8.92 percent. It remains about 6.4 percent below its 52-week high of €55.05, reached in April.
One Eye on the Rhine
Not everything is running smoothly. Persistent low water levels at the Kaub gauge on the Rhine are pushing up transport costs and causing sporadic supply disruptions at the Ludwigshafen site, according to media reports. If the dry spell continues, production schedules could face further strain — a recurring vulnerability for the location that BASF will need to monitor closely in the weeks ahead.
For investors, the central question is whether the operational strength of the second quarter, reinforced by buybacks and the new US sunscreen opportunity, can carry the stock back toward its yearly peak — while the Rhine's shrinking water levels remain a watch item in the background.
